Topics:

Lung Cancer

On November 19, New York City Mayor Michael Bloomberg signed legislation (Tobacco 21 [Intro 250-A]) making New York the first major city to ban the sale of cigarettes, certain tobacco products, and e-cigarettes to anyone under 21 years of age, up from age 18.

Lung Cancer

New research has shown that a new assay for measuring circulating tumor DNA (ctDNA) could detect essentially all stage II-IV non-small-cell lung cancers (NSCLC).

A combination of amrubicin and cisplatin was inferior to irinotecan and cisplatin in chemotherapy-naïve patients with extensive disease small-cell lung cancer (SCLC) in a phase III trial conducted in Japan.

GlaxoSmithKline has stopped a phase III trial of a novel lung cancer immunotherapeutic agent, after determining that it may not be possible to identify which genetic subgroups may benefit from the treatment.

A biomarker and five clinical factors help to predict which patients with nonsmall-cell lung cancer are at high risk for lung inflammation after radiotherapy.

The new ALK inhibitor certinib showed strong antitumor activity in a phase I expansion study of patients with advanced non-small-cell lung cancer (NSCLC).

In a phase I trial, non–small-cell lung cancer (NSCLC) patients with tumors that expressed PD-L1 had significantly better outcomes with MK-3475 therapy compared with patients with PD-L1–negative tumors.

In summary, central lung cancers, when appropriately staged, are optimally treated by surgical resection. Initial evaluation is best done by a multidisciplinary team, involving a trained thoracic surgeon.

Pages

Subscribe to
Please Wait 20 seconds or click here to close